A Clear Horizon in Plaque Psoriasis: Exploring the Role of Investigational Oral Therapies
13 mins; January 24, 2025
Acute Kidney Injury in Cirrhosis: Multidisciplinary Decision-Making
35 mins; January 23, 2025
Balancing Act: Immune Reconstitution vs. Immune Suppression
5 mins; January 23, 2025
Brain Health in MS: A Comprehensive Approach
5 mins; January 23, 2025
Fluid Biomarkers: Revolutionizing MS Diagnosis
5 mins; January 23, 2025
From Pathology to Practice: The Role of Inflammation in MS Pathology
5 mins; January 23, 2025
High-Efficacy DMTs: Transforming MS Care
5 mins; January 23, 2025
Imaging Biomarkers: MS Progression in Focus
5 mins; January 23, 2025
Long-Term Safety of DMTs: What We Know and What We Need to Know
5 mins; January 23, 2025
MS Cognitive Insights: Management, Diagnostic, and Treatment Strategies
5 mins; January 23, 2025
Personalized Care for Diverse MS Populations: Special Populations Equal Special Care
4 mins; January 23, 2025
Preparing the Patient with Decompensated Cirrhosis for Liver Transplant: ICU Discussions, Considerations and Dialysis
21 mins; January 23, 2025
PROs in MS: A New Era of Patient-Centric Care
5 mins; January 23, 2025
Clinical trial evidence that drives current guidelines for patients with CLL/SLL and MCL receiving third-line therapies
5 mins; January 22, 2025
Emerging data with potentially guideline-changing implications in CLL/SLL and MCL
6 mins; January 22, 2025
Guideline-recommended treatment options for patients with CLL/SLL and MCL that have progressed following a covalent BTK inhibitor
6 mins; January 22, 2025
Incorporating guideline-concordant care for patients with CLL/SLL relapsing after 2 prior lines of therapy
6 mins; January 22, 2025
Autoantibodies in MG: Their Role in Diagnosis and Treatment
4 mins; January 16, 2025
Balancing Risk and Benefit: Traditional MG Treatments and Medications to Avoid
4 mins; January 16, 2025
Beyond the Symptoms: The True Impact of gMG on Patients' Lives
5 mins; January 16, 2025
Diagnosing gMG: Navigating Current Tools and Approaches
5 mins; January 16, 2025
Evaluation and Management of AKI in Cirrhosis: At the Interface of Gastroenterology and Nephrology
14 mins; January 16, 2025
FcRn Antagonists in Myasthenia Gravis: A New Era in Targeted Therapy
5 mins; January 16, 2025
Life-Threatening Events: Understanding and Preventing Myasthenic Crisis
5 mins; January 16, 2025
Optimizing FcRn Therapy: Addressing and Reducing Adverse Reactions
5 mins; January 16, 2025
Precision Medicine in Myasthenia Gravis: Crafting Personalized Treatment Strategies
4 mins; January 16, 2025
The Science Behind FcRn Antagonists: A Deep Dive Into Their Mechanism of Action
4 mins; January 16, 2025
Understanding Disease Progression: The Shift From Ocular to Generalized MG
5 mins; January 16, 2025
Unique New Strategies for the Pharmacologic Treatment of Dry Eye Disease: Focus
46 mins; January 15, 2025
Breaking the Cycle: Addressing Hyperkalemia in CKD and Heart Failure to Optimize RAASi Therapy
14 mins; January 14, 2025
Maximizing Myeloma Outcomes With GPRC5D-Directed Therapy: Practical Expert Case Studies and Best Practices
14 mins; January 14, 2025
Chairperson's Perspective: Novel Treatments for Newly Diagnosed Ph+ CML-CP: Striking the Balance of Treatment With Patient Goals and QoL
20 mins; January 13, 2025
Chemotherapy Strategies for Metastatic PDAC
5 mins; January 12, 2025
Diagnosis and Management of Metastatic PDAC
4 mins; January 12, 2025
Elevating HF Care With ns-MRAs: The Future Is Now
5 mins; January 09, 2025
ns-MRAs and Biomarkers: The NT-proBNP Connection
6 mins; January 09, 2025
A Global Health Crisis
4 mins; December 30, 2024
Breaking the Bias: Addressing Stigma in Obesity Care
5 mins; December 30, 2024
Diagnosing Obesity: Beyond BMI
4 mins; December 30, 2024
Personalized Obesity Management: A Comprehensive Approach
5 mins; December 30, 2024
Pharmacotherapy in Obesity: Current and Emerging Options
6 mins; December 30, 2024
Pulmonary Hypertension: Diagnosis, Management, and Updates – Chairperson’s Perspective
15 mins; December 30, 2024
Recent Guidelines Updates: Implications to Practice
5 mins; December 30, 2024
The Power of Shared Decision-Making in Obesity Care
8 mins; December 30, 2024
The Power of Teamwork: Multidisciplinary Obesity Care
5 mins; December 30, 2024
Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
6 mins; December 29, 2024
Applying Current Guidelines in the First-Line Treatment of MSI-H/dMMR mCRC—A Case Discussion
5 mins; December 29, 2024
Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
6 mins; December 29, 2024
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
6 mins; December 29, 2024
Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC
7 mins; December 29, 2024
Emerging Directions in Biomarker-Directed Therapy for GI Malignancies
6 mins; December 29, 2024
Emerging Treatment Approaches for EBC
7 mins; December 29, 2024
Expert Opinion: Key Insights on GI Malignancies—Integrating NCCN Clinical Practice Guidelines Into Practice
10 mins; December 29, 2024
Expert Viewpoint: Optimizing Breast Cancer Treatment
19 mins; December 29, 2024
First-Line Advanced Gastric Cancer: Best Practices for Biomarker-Directed Treatment Approaches—A Case Study
5 mins; December 29, 2024
First-line Treatment of MSI-H/dMMR mCRC: The Role of Immunotherapy
4 mins; December 29, 2024
Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer
6 mins; December 29, 2024
Immunotherapy-Based Approaches for First-Line Treatment of Advanced HCC: The Evidence
7 mins; December 29, 2024
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
6 mins; December 29, 2024
Management of HER2-Low MBC Following First-Line Disease Progression
7 mins; December 29, 2024
Management of HR+, HER2- High-Risk EBC
7 mins; December 29, 2024
Novel Neoadjuvant and Adjuvant Immunotherapy Strategies for GI Malignancies: The Evidence
6 mins; December 29, 2024
The Evolving Treatment Landscape for MBC: Emerging Therapies
10 mins; December 29, 2024
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
5 mins; December 29, 2024
The Role of HER2-Directed Therapy for Second-Line Treatment of HER2+ Metastatic Breast Cancer
5 mins; December 29, 2024
Unmasking IgAN: From Suspicion to Timely Diagnosis
20 mins; December 29, 2024
TIME OUT: A Case-Based Deep Dive into the Challenges of ARIA Management
48 mins; December 22, 2024
Advancing ALK Inhibition Into Early-Stage NSCLC: Integrating Biomarker-Driven Therapies to Reduce Recurrence Risk Post Resection
15 mins; December 19, 2024
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
7 mins; December 19, 2024
Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer
6 mins; December 19, 2024
Emerging immunotherapy combination strategies in genitourinary malignancies
6 mins; December 19, 2024
Emerging targeted therapy combination strategies in genitourinary malignancies
6 mins; December 19, 2024
Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer
6 mins; December 19, 2024
Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma
5 mins; December 19, 2024
Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma
7 mins; December 19, 2024
Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma
7 mins; December 19, 2024
Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naĂŻve to both docetaxel and novel hormone therapy
7 mins; December 19, 2024
Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies
7 mins; December 19, 2024
Pulmonary Hypertension: Comorbidities With PAH and Group 2 PH
53 mins; December 19, 2024
Pulmonary Hypertension Management: Practice Trends and Updates
56 mins; December 19, 2024
Risk Assessment in Pulmonary Hypertension: Practice Trends and Updates
58 mins; December 19, 2024
An Overview of ARIA: A Multidisciplinary Crash Course for Baseline Clinical Needs
45 mins; December 18, 2024
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
13 mins; December 17, 2024
Biologic Rationale for Targeting HER3 and Role in EGFR Resistance
5 mins; December 16, 2024
Case Application: Patients With EGFRm Resistance Post TKI and Platinum Chemotherapy
5 mins; December 16, 2024
Case Application: Patients With EGFRm Resistance Post TKI and Platinum Chemotherapy
5 mins; December 16, 2024
Expert Peer Discussion: Integrating Novel HER3-Directed ADCs Upon Disease Progression Following EGFR TKI and Platinum Chemotherapy
5 mins; December 16, 2024
Interprofessional Monitoring and Management of AEs With HER3-Directed ADCs
5 mins; December 16, 2024
Overcoming EGFR Resistance With HER3-Directed ADCs
4 mins; December 16, 2024
The Changing Paradigm of Treating MASLD/MASH: At the Crossroads of Hepato-Cardiometabolic Care – Chair’s Perspective
13 mins; December 16, 2024
COPD Care: Partnership Between Primary Care and Pulmonary Providers
14 mins; December 15, 2024
Finally, I Can Take a Break from My Itch! Optimizing CKD-aP Treatment
14 mins; December 15, 2024
Advances in IgAN Care From Kidney Week
13 mins; December 12, 2024
Best Practices for Identifying, Diagnosing and Treating Transthyretin Amyloidosis (ATTR-PN and ATTR-CM)
31 mins; December 12, 2024
The Shifting ATTR-CM Landscape: Early Diagnosis, Emerging Therapies & Personalized Care
25 mins; December 12, 2024
The Weight of Recurrence: Navigating Multidisciplinary Care Planning in Recurring/Metastatic Cervical Cancer
14 mins; December 05, 2024
Advances in the Treatment and Management of MASH: More Options, More Decisions
0 secs; December 03, 2024
[QA] test create new segment
46 mins; November 30, 2024
Application of guidelines-recommended broad molecular profiling to patients with NSCLC
0 secs; November 26, 2024
Clinical evidence behind emerging targeted therapy strategies in patients with metastatic NSCLC
